Company Executives

Management Team

From the 10-K annual report

Officer	Age	In this role	Joined	2025 pay
Birgit Girshick Chief Executive Officer Title from the Form 4 dated Aug 19, 2026	56	Since 2021 5 years	1989	Not reported
Glenn Coleman EVP & Chief Financial Officer Title from the Form 4 dated Sep 30, 2026	Not stated	Not stated	Not stated	Not reported
Victoria Creamer EVP & Chief People Officer Title from the Form 4 dated Aug 6, 2026	56	Not stated	2019	Not reported
Michael Knell SVP, Finance and CAO Title from the Form 4 dated Aug 6, 2026	49	Not stated	2017	$2,107,684
Mark Mintz Corporate Executive Vice President, Chief Information Officer & Global Shared Services	52	Since 2025 1 year	2021	Not reported
Joseph LaPlume EVP, Corp Strategy & Develop Title from the Form 4 dated Aug 10, 2026	52	Not stated	Not stated	Not reported
Shannon Parisotto CEVP, Disc & Safety Assessment Title from the Form 4 dated Oct 21, 2026	52	Not stated	2000	Not reported

Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.

Board of Directors

From the proxy statement filed Mar 31, 2026

Directors

serving now

Independent

9 of 11

stated in the proxy

Average tenure

6.8 years

from year joined

CEO also chairs the board

Yes

James C. Foster and Martin W. Mackay

Director	Age	On board	Independent	Committees	Other public boards	2025 pay
James C. Foster Board chair, CEO	75	1989 37 years	Not independent	None stated	None stated	Paid as CEO
Martin W. Mackay Lead independent director, Board chair	70	2017 9 years	Independent	None stated	Rallybio Corporation	$365,859
Nancy C. Andrews	67	2020 6 years	Independent	None stated	Novartis International AG, Maze Therapeutics	$340,859
Steven Barg	64	2025 1 year	Independent	None stated	None stated	$320,708
Abraham Ceesay	48	2025 1 year	Not independent	New Approach Methodologies and Science Committee	Rapport Therapeutics, Pacira Biosciences	$320,708
Mark Enyedy	62	2025 1 year	Independent	None stated	Astellas Pharma, BioMarin, Ergomed plc	Not stated
Paul Graves	55	2025 1 year	Independent	None stated	None stated	$345,708
Reshema Kemps-Polanco	53	2024 2 years	Independent	None stated	None stated	$340,859
George Llado Sr.	60	2020 6 years	Independent	None stated	TraceLink Inc.	$325,859
Craig B. Thompson	73	2022 4 years	Independent	None stated	Regeneron Pharmaceuticals, Inc.	$340,859
Virginia M. Wilson	71	2019 7 years	Independent	None stated	Carrier Global Corporation	$345,859

Nominated to join at the meeting

Not on the board yet; they join only if elected.

Birgit Girshick · 56

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

No related-party transactions disclosed

The proxy filed Mar 31, 2026 states there were none.

Read it in the proxy

Comments

Company Executives

Management Team

Board of Directors

Related-party transactions

No related-party transactions disclosed